SentreHEART, Inc.
Founded in 2005, SentreHEART is focused on remote suture delivery for immediate and complete closure of anatomic structures. SentreHEART is committed to clinical evidence development and is currently sponsoring the FDA-approved prospective, multi-center, randomized controlled trial known as the aMAZE Trial. This trial is designed to demonstrate the additive benefits of LARIAT LAA closure combined with pulmonary vein isolation as a means of improving outcomes in patients with persistent or longstanding persistent atrial fibrillation.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Clinical Services
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2005
About Us
SentreHEART is committed to clinical evidence development and is currently sponsoring the FDA-approved prospective, multi-center, randomized controlled trial known as the aMAZE Trial. This trial is designed to demonstrate the additive benefits of LARIAT LAA closure combined with pulmonary vein isolation as a means of improving outcomes in patients with persistent or longstanding persistent atrial fibrillation.